Cargando…

Hyperbaric oxygen rapidly improves tissue-specific insulin sensitivity and mitochondrial capacity in humans with type 2 diabetes: a randomised placebo-controlled crossover trial

AIMS/HYPOTHESIS: Hyperbaric oxygen (HBO) therapy may improve hyperglycaemia in humans with type 2 diabetes, but underlying mechanisms are unclear. Our objective was to examine the glucometabolic effects of HBO on whole-body glucose disposal in humans with type 2 diabetes. METHODS: In a randomised pl...

Descripción completa

Detalles Bibliográficos
Autores principales: Sarabhai, Theresia, Mastrototaro, Lucia, Kahl, Sabine, Bönhof, Gidon J., Jonuscheit, Marc, Bobrov, Pavel, Katsuyama, Hisayuki, Guthoff, Rainer, Wolkersdorfer, Martin, Herder, Christian, Meuth, Sven G., Dreyer, Sven, Roden, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9729133/
https://www.ncbi.nlm.nih.gov/pubmed/36178534
http://dx.doi.org/10.1007/s00125-022-05797-0
_version_ 1784845418338713600
author Sarabhai, Theresia
Mastrototaro, Lucia
Kahl, Sabine
Bönhof, Gidon J.
Jonuscheit, Marc
Bobrov, Pavel
Katsuyama, Hisayuki
Guthoff, Rainer
Wolkersdorfer, Martin
Herder, Christian
Meuth, Sven G.
Dreyer, Sven
Roden, Michael
author_facet Sarabhai, Theresia
Mastrototaro, Lucia
Kahl, Sabine
Bönhof, Gidon J.
Jonuscheit, Marc
Bobrov, Pavel
Katsuyama, Hisayuki
Guthoff, Rainer
Wolkersdorfer, Martin
Herder, Christian
Meuth, Sven G.
Dreyer, Sven
Roden, Michael
author_sort Sarabhai, Theresia
collection PubMed
description AIMS/HYPOTHESIS: Hyperbaric oxygen (HBO) therapy may improve hyperglycaemia in humans with type 2 diabetes, but underlying mechanisms are unclear. Our objective was to examine the glucometabolic effects of HBO on whole-body glucose disposal in humans with type 2 diabetes. METHODS: In a randomised placebo-controlled crossover trial located at the German Diabetes Center, 12 male individuals with type 2 diabetes (age 18–75 years, BMI <35 kg/m(2), HbA(1c) 42–75 mmol/mol [6–9%]), randomly allocated by one person, underwent 2-h HBO, once with 100% (240 kPa; HBO) and once with 21% oxygen (240 kPa; control, CON). Insulin sensitivity was assessed by hyperinsulinaemic–euglycaemic clamps with d-[6,6-(2)H(2)]glucose, hepatic and skeletal muscle energy metabolism were assessed by (1)H/(31)P-magnetic resonance spectroscopy, while high-resolution respirometry measured skeletal muscle and white adipose tissue (WAT) mitochondrial capacity. All participants and people assessing the outcomes were blinded. RESULTS: HBO decreased fasting blood glucose by 19% and increased whole-body, hepatic and WAT insulin sensitivity about one-third (p<0.05 vs CON). Upon HBO, hepatic γ-ATP concentrations doubled, mitochondrial respiratory control doubled in skeletal muscle and tripled in WAT (p<0.05 vs CON). HBO increased myocellular insulin-stimulated serine-473/threonine-308 phosphorylation of Akt but decreased basal inhibitory serine-1101 phosphorylation of IRS-1 and endoplasmic reticulum stress (p<0.05 vs CON). CONCLUSIONS/INTERPRETATION: HBO-mediated improvement of insulin sensitivity likely results from decreased endoplasmic reticulum stress and increased mitochondrial capacity, possibly leading to low-dose reactive oxygen species-mediated mitohormesis in humans with type 2 diabetes. TRIAL REGISTRATION: ClinicalTrials.gov NCT04219215 FUNDING: German Federal Ministry of Health, German Federal Ministry of Education and Research, North-Rhine Westfalia Ministry of Culture and Science, European-Regional-Development-Fund, German-Research-Foundation (DFG), Schmutzler Stiftung GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version of this article (10.1007/s00125-022-05797-0) contains peer-reviewed but unedited supplementary material..
format Online
Article
Text
id pubmed-9729133
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-97291332022-12-09 Hyperbaric oxygen rapidly improves tissue-specific insulin sensitivity and mitochondrial capacity in humans with type 2 diabetes: a randomised placebo-controlled crossover trial Sarabhai, Theresia Mastrototaro, Lucia Kahl, Sabine Bönhof, Gidon J. Jonuscheit, Marc Bobrov, Pavel Katsuyama, Hisayuki Guthoff, Rainer Wolkersdorfer, Martin Herder, Christian Meuth, Sven G. Dreyer, Sven Roden, Michael Diabetologia Article AIMS/HYPOTHESIS: Hyperbaric oxygen (HBO) therapy may improve hyperglycaemia in humans with type 2 diabetes, but underlying mechanisms are unclear. Our objective was to examine the glucometabolic effects of HBO on whole-body glucose disposal in humans with type 2 diabetes. METHODS: In a randomised placebo-controlled crossover trial located at the German Diabetes Center, 12 male individuals with type 2 diabetes (age 18–75 years, BMI <35 kg/m(2), HbA(1c) 42–75 mmol/mol [6–9%]), randomly allocated by one person, underwent 2-h HBO, once with 100% (240 kPa; HBO) and once with 21% oxygen (240 kPa; control, CON). Insulin sensitivity was assessed by hyperinsulinaemic–euglycaemic clamps with d-[6,6-(2)H(2)]glucose, hepatic and skeletal muscle energy metabolism were assessed by (1)H/(31)P-magnetic resonance spectroscopy, while high-resolution respirometry measured skeletal muscle and white adipose tissue (WAT) mitochondrial capacity. All participants and people assessing the outcomes were blinded. RESULTS: HBO decreased fasting blood glucose by 19% and increased whole-body, hepatic and WAT insulin sensitivity about one-third (p<0.05 vs CON). Upon HBO, hepatic γ-ATP concentrations doubled, mitochondrial respiratory control doubled in skeletal muscle and tripled in WAT (p<0.05 vs CON). HBO increased myocellular insulin-stimulated serine-473/threonine-308 phosphorylation of Akt but decreased basal inhibitory serine-1101 phosphorylation of IRS-1 and endoplasmic reticulum stress (p<0.05 vs CON). CONCLUSIONS/INTERPRETATION: HBO-mediated improvement of insulin sensitivity likely results from decreased endoplasmic reticulum stress and increased mitochondrial capacity, possibly leading to low-dose reactive oxygen species-mediated mitohormesis in humans with type 2 diabetes. TRIAL REGISTRATION: ClinicalTrials.gov NCT04219215 FUNDING: German Federal Ministry of Health, German Federal Ministry of Education and Research, North-Rhine Westfalia Ministry of Culture and Science, European-Regional-Development-Fund, German-Research-Foundation (DFG), Schmutzler Stiftung GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version of this article (10.1007/s00125-022-05797-0) contains peer-reviewed but unedited supplementary material.. Springer Berlin Heidelberg 2022-09-30 2023 /pmc/articles/PMC9729133/ /pubmed/36178534 http://dx.doi.org/10.1007/s00125-022-05797-0 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Sarabhai, Theresia
Mastrototaro, Lucia
Kahl, Sabine
Bönhof, Gidon J.
Jonuscheit, Marc
Bobrov, Pavel
Katsuyama, Hisayuki
Guthoff, Rainer
Wolkersdorfer, Martin
Herder, Christian
Meuth, Sven G.
Dreyer, Sven
Roden, Michael
Hyperbaric oxygen rapidly improves tissue-specific insulin sensitivity and mitochondrial capacity in humans with type 2 diabetes: a randomised placebo-controlled crossover trial
title Hyperbaric oxygen rapidly improves tissue-specific insulin sensitivity and mitochondrial capacity in humans with type 2 diabetes: a randomised placebo-controlled crossover trial
title_full Hyperbaric oxygen rapidly improves tissue-specific insulin sensitivity and mitochondrial capacity in humans with type 2 diabetes: a randomised placebo-controlled crossover trial
title_fullStr Hyperbaric oxygen rapidly improves tissue-specific insulin sensitivity and mitochondrial capacity in humans with type 2 diabetes: a randomised placebo-controlled crossover trial
title_full_unstemmed Hyperbaric oxygen rapidly improves tissue-specific insulin sensitivity and mitochondrial capacity in humans with type 2 diabetes: a randomised placebo-controlled crossover trial
title_short Hyperbaric oxygen rapidly improves tissue-specific insulin sensitivity and mitochondrial capacity in humans with type 2 diabetes: a randomised placebo-controlled crossover trial
title_sort hyperbaric oxygen rapidly improves tissue-specific insulin sensitivity and mitochondrial capacity in humans with type 2 diabetes: a randomised placebo-controlled crossover trial
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9729133/
https://www.ncbi.nlm.nih.gov/pubmed/36178534
http://dx.doi.org/10.1007/s00125-022-05797-0
work_keys_str_mv AT sarabhaitheresia hyperbaricoxygenrapidlyimprovestissuespecificinsulinsensitivityandmitochondrialcapacityinhumanswithtype2diabetesarandomisedplacebocontrolledcrossovertrial
AT mastrototarolucia hyperbaricoxygenrapidlyimprovestissuespecificinsulinsensitivityandmitochondrialcapacityinhumanswithtype2diabetesarandomisedplacebocontrolledcrossovertrial
AT kahlsabine hyperbaricoxygenrapidlyimprovestissuespecificinsulinsensitivityandmitochondrialcapacityinhumanswithtype2diabetesarandomisedplacebocontrolledcrossovertrial
AT bonhofgidonj hyperbaricoxygenrapidlyimprovestissuespecificinsulinsensitivityandmitochondrialcapacityinhumanswithtype2diabetesarandomisedplacebocontrolledcrossovertrial
AT jonuscheitmarc hyperbaricoxygenrapidlyimprovestissuespecificinsulinsensitivityandmitochondrialcapacityinhumanswithtype2diabetesarandomisedplacebocontrolledcrossovertrial
AT bobrovpavel hyperbaricoxygenrapidlyimprovestissuespecificinsulinsensitivityandmitochondrialcapacityinhumanswithtype2diabetesarandomisedplacebocontrolledcrossovertrial
AT katsuyamahisayuki hyperbaricoxygenrapidlyimprovestissuespecificinsulinsensitivityandmitochondrialcapacityinhumanswithtype2diabetesarandomisedplacebocontrolledcrossovertrial
AT guthoffrainer hyperbaricoxygenrapidlyimprovestissuespecificinsulinsensitivityandmitochondrialcapacityinhumanswithtype2diabetesarandomisedplacebocontrolledcrossovertrial
AT wolkersdorfermartin hyperbaricoxygenrapidlyimprovestissuespecificinsulinsensitivityandmitochondrialcapacityinhumanswithtype2diabetesarandomisedplacebocontrolledcrossovertrial
AT herderchristian hyperbaricoxygenrapidlyimprovestissuespecificinsulinsensitivityandmitochondrialcapacityinhumanswithtype2diabetesarandomisedplacebocontrolledcrossovertrial
AT meuthsveng hyperbaricoxygenrapidlyimprovestissuespecificinsulinsensitivityandmitochondrialcapacityinhumanswithtype2diabetesarandomisedplacebocontrolledcrossovertrial
AT dreyersven hyperbaricoxygenrapidlyimprovestissuespecificinsulinsensitivityandmitochondrialcapacityinhumanswithtype2diabetesarandomisedplacebocontrolledcrossovertrial
AT rodenmichael hyperbaricoxygenrapidlyimprovestissuespecificinsulinsensitivityandmitochondrialcapacityinhumanswithtype2diabetesarandomisedplacebocontrolledcrossovertrial